KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
Michele Maio(University of Siena), Omid Hamid(Cedars-Sinai Medical Center), Marcus O. Butler(University of Toronto), Robert Zielinski, Pier Francesco Ferrucci(MultiMedica), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Wilson H. Miller(Jewish General Hospital), Razi Ghori(Merck & Co., Inc., Rahway, NJ, USA (United States)), Eduard Gasal, Scott J. Diede(Merck & Co., Inc., Rahway, NJ, USA (United States)), Matteo S. Carlino(The University of Sydney), Antoni Ribas(University of California, Los Angeles), Anthony M. Joshua(St Vincent's Hospital Sydney), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Elizabeth Croydon(Merck & Co., Inc., Rahway, NJ, USA (United States)), Elaine McWhirter(Juravinski Cancer Centre)
Cited by 10
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k